글로벌 알부민 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

알부민 시장 분석

알부민 시장은 치료제, 약물 전달 및 배양 배지에서 응용 분야가 증가함에 따라 역동적인 성장을 경험하고 있습니다. 시장에서 주목할 만한 발전은 알부민 생산의 효율성과 수율을 모두 개선하는 혈장 분획 기술의 발전입니다. 예를 들어, Kedrion Biopharma와 같은 회사는 희귀 질환 치료에 대한 요구를 충족하기 위해 중국과 같은 신흥 시장에서 인간 혈청 알부민 제품을 확대하고 있습니다. 또한 유전 공학을 통해 생산된 재조합 알부민으로의 전환은 기존 인간 혈청 알부민에 비해 우수한 안전성 프로필과 일관성으로 인해 인기를 얻고 있습니다. 이러한 추세는 Grifols가 임상 연구 및 제약 응용 분야에서 점점 더 많이 사용되는 Albutein을 출시한 것에서 잘 알 수 있습니다. 또한 특히 북미에서 연구 개발에 대한 투자가 증가함에 따라 혁신이 가속화되고 생산 공정이 개선되고 있습니다. 포괄적인 발전은 알부민 시장의 견고한 성장과 다각화에 기여하여 의료 및 연구 분야의 변화하는 요구 사항을 충족합니다.

알부민 시장 규모

글로벌 알부민 시장 규모는 2023년에 10억 1,000만 달러로 평가되었으며, 2031년까지 16억 2,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.00%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

알부민 시장 동향

“ 재조합 알부민의 사용 증가”

글로벌 알부민 시장은 생산 기술의 발전과 치료적 응용 분야에 대한 수요 증가에 영향을 받아 상당한 성장을 목격하고 있습니다. 시장에서 두드러진 추세는 재조합 알부민의 사용 증가입니다. 전통적인 인간 혈청 알부민과 달리 재조합 알부민은 유전 공학 기술을 사용하여 생산되어 순도가 향상되고 오염 위험이 줄어듭니다. 예를 들어 Grifols는 약물 전달 시스템 및 임상 연구를 포함한 다양한 의료 치료에 사용되는 재조합 알부민 제품인 Albutein으로 선두에 섰습니다. 재조합 알부민으로의 이러한 전환은 보다 안전하고 일관된 치료 옵션에 대한 필요성에 의해 주도됩니다. 오염 없는 고품질 제품에 대한 강조가 커지면서 의료 서비스 제공자와 연구자가 환자 치료와 과학적 탐구의 진화하는 요구를 충족하기 위해 이러한 고급 솔루션을 점점 더 많이 채택함에 따라 시장 성장이 더욱 촉진될 것으로 예상됩니다.

보고서 범위 및 알부민 시장 세분화     

Albumin Market Definition

Albumin is a type of protein found in blood plasma that plays a crucial role in maintaining the osmotic pressure necessary for proper distribution of body fluids between blood vessels and tissues. It is produced primarily in the liver and is essential for various physiological functions, including transporting hormones, vitamins, and drugs through the bloodstream. Albumin also helps in stabilizing blood volume and pressure. In medical applications, albumin is used as a therapeutic agent to treat conditions such as liver disease, kidney disease, and shock, as well as in drug delivery systems and clinical research.

Albumin Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases significantly drives the demand for albumin-based therapies. For instance, the World Health Organization reported in 2023 that chronic liver disease is responsible for nearly 2 billion deaths annually, with liver cirrhosis being a leading cause. In the United States alone, approximately 1.2 billion people are affected by liver cirrhosis, highlighting the need for effective management strategies. Albumin is crucial in these conditions for stabilizing blood volume and improving fluid balance, thereby supporting patient outcomes. Additionally, the prevalence of chronic kidney disease affects over 10% of the global population, with an estimated 840 billion individuals, according to the Global Burden of Disease Study. This widespread occurrence drives the need for albumin therapies to manage complications such as hypoalbuminemia. These figures emphasize the essential role of albumin in addressing chronic diseases and underscore its growing importance in therapeutic interventions.

• Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure in emerging markets is a crucial driver of growth in the global albumin market. For instance, India's healthcare sector is anticipated to reach USD 370 billion by 2025, supported by significant improvements in hospital networks and enhanced access to advanced medical care. This burgeoning infrastructure includes the development of state-of-the-art medical facilities and the introduction of innovative treatments, which elevate the availability of specialized therapies such as albumin-based products. Consequently, the growing investment in healthcare infrastructure not only boosts the reach of albumin therapies but also supports the overall market expansion by addressing the increasing demand for effective medical solutions across diverse patient populations. Such trend underscores the vital role of infrastructure development in driving the global albumin market forward.

Opportunities

• Growing Use in Drug Delivery Systems

The growing use of albumin in drug delivery systems is significantly enhancing therapeutic efficacy due to its unique properties as a transport protein. Albumin's ability to bind and carry a variety of therapeutic agents makes it ideal for improving the targeting and release of drugs within the body. For instance, Abraxane, an albumin-bound formulation of paclitaxel, is used in cancer treatment to deliver the drug directly to tumor cells more effectively than conventional paclitaxel formulations. Such targeted approach not only increases the drug's bioavailability but also reduces side effects by minimizing exposure to healthy tissues. As the demand for more precise and efficient drug delivery methods rises, albumin's role continues to expand, driven by its capacity to enhance the delivery and effectiveness of therapeutic agents while improving patient outcomes.

• Advancements in Plasma Fractionation Technology

Advancements in plasma fractionation technology are significantly improving the efficiency and yield of albumin production, leading to a greater availability of high-quality albumin products. Modern fractionation techniques, such as the use of high-resolution chromatography and advanced filtration methods, have revolutionized the separation and purification of plasma proteins. For instance, Octapharma has implemented cutting-edge fractionation processes that enhance the purity and yield of albumin extracted from plasma, resulting in a more reliable and consistent product. Such technological improvements not only increase the volume of albumin available for therapeutic use but also ensure higher quality and safety standards, meeting the growing demand for albumin-based treatments. As these innovations continue to evolve, they play a crucial role in expanding the global supply of albumin and supporting its application in various medical and research settings.

Restraints/Challenges

• Regulatory Hurdles and Stringent Requirements

Regulatory hurdles are a significant challenge in the albumin market, where stringent requirements can impede market entry and elevate operational costs. For instance, to gain approval from the U.S. Food and Drug Administration (FDA), albumin products must undergo extensive clinical trials and meet detailed documentation standards. According to a 2023 report by the FDA, the average time for a new biologics license application to be reviewed is approximately 10 months. Similarly, the European Medicines Agency (EMA) requires compliance with the European Union's Regulation (EC) No 726/2004 and the guidelines outlined in the "European Pharmacopoeia," demanding comprehensive safety and efficacy data. Such rigorous standards can delay product launches and significantly increase development costs. Compliance with these regulatory frameworks necessitates substantial investments in research, quality control, and documentation, affecting both time-to-market and the financial viability of new albumin products.

• Absurd Uses and Adverse Reactions Associated with Albumin

The rising challenge in the albumin market is the occurrence of adverse reactions and the reporting of unusual uses associated with albumin. Administration of albumin can lead to allergic reactions, febrile non-hemolytic transfusion reactions (FNHTR), and anaphylaxis. Additionally, there are concerns about the misuse of albumin in non-medical applications, such as certain cosmetic procedures and unregulated treatments, which pose potential health risks. The World Health Organization (WHO) has emphasized the need for stringent regulations and monitoring to address these issues. Consequently, such factors can hinder market growth by impacting safety and regulatory compliance.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Albumin Market Scope

The market is segmented on the basis of type, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Application

• Therapeutics
• Vaccine Ingredient
• Drug Delivery
• Culture Media
• Others

End User

• Hospitals
• Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Albumin Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The Asia-Pacific region dominates the albumin market due to its large and rapidly growing population, coupled with a significant emphasis on advancing diagnostic capabilities, preventive treatments, and medical research. The region's expanding healthcare infrastructure and increasing investments in research and development further drive the demand for albumin products.

North America is projected to experience substantial growth from 2024 to 2031, driven by the increasing establishment of plasma fractionation facilities which boost albumin production. Additionally, the region's heightened investment in research and development further supports this expansion. These factors collectively contribute to North America's robust growth outlook in the albumin market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Albumin Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Albumin Market Leaders Operating in the Market Are:

• Octapharma AG (Switzerland)
• CSL (Australia)
• Baxter (U.S.)
• HiMedia Laboratories (India)
• MedxBio Pte Ltd (Singapore)
• Novozymes A/S (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Merck KGaA (Germany)
• Akron Biotech (U.S.)
• China Biologic Products Holdings, Inc. (중국)
• Thermo Fisher Scientific Inc. (미국)
• Thrive Supplements (미국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 케드리온 SpA(이탈리아)
• 그리폴스, SA(스페인)
• 인비트리아(미국)
• 알부민 테라퓨틱스, LLC (미국)
• 레이바이오텍 주식회사(미국)
• LGC 임상진단(영국)

알부민 시장의 최신 동향

• 2022년 8월, Sartorius AG는 재조합 인간 알부민 기반 제품을 전문으로 하는 영국의 선도적 제조업체인 Albumedix Ltd.를 인수했습니다. 이 전략적 인수는 특히 재조합 기반 솔루션 분야에서 Sartorius AG의 제품 포트폴리오를 크게 강화할 예정입니다.
• 2023년 7월, 혈장 유래 치료제 분야의 글로벌 리더인 Kedrion Biopharma는 중국에서 인간 혈청 알부민 제품 범위를 확장할 계획을 밝혔습니다. 이 전략적 움직임은 이 지역의 희귀 질환 치료에 대한 증가하는 수요를 해결하는 것을 목표로 합니다. Kedrion Biopharma는 중국 시장에서의 입지를 강화함으로써 특수 의료적 요구가 있는 환자를 위한 중요한 치료제에 대한 접근성을 개선하고자 합니다.

SKU-30377